Get started
Keyword

niraparib

Description: An anticancer drug that inhibits poly(ADP-ribose) polymerase and is used in maintenance treatment for certain ovarian cancers.
Wikidata ID: wiki/Q25326660
OpenAlex ID: keywords/niraparib
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
2016 · Mansoor R. Mirza, Bradley J. Monk, et al. · New England Journal of Medicine · 2,454
PDF
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
2019 · Antonio González-Martín, Bhavana Pothuri, et al. · New England Journal of Medicine · 2,267
PDF
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
2012 · Junko Murai, Shar-yin N. Huang, et al. · Cancer Research · 2,197
A decade of clinical development of PARP inhibitors in perspective
2019 · J. Mateo, C.J. Lord, et al. · Annals of Oncology · 733
PARP and PARG inhibitors in cancer treatment
2020 · Dea Slade · Genes & Development · 668
PDF
Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma
2019 · Panagiotis A. Konstantinopoulos, Steven Waggoner, et al. · JAMA Oncology · 564
PDF
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
2013 · Shahneen K Sandhu, William R Schelman, et al. · The Lancet Oncology · 562
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
2019 · Kathleen N Moore, Angeles Alvarez Secord, et al. · The Lancet Oncology · 535
Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer
2019 · Shaveta Vinayak, Sara M. Tolaney, et al. · JAMA Oncology · 454
PDF
An Overview of PARP Inhibitors for the Treatment of Breast Cancer
2021 · Laura Cortesi, Hope S. Rugo, et al. · Targeted Oncology · 393
PDF
The forefront of ovarian cancer therapy: update on PARP inhibitors
2020 · M.R. Mirza, R.L. Coleman, et al. · Annals of Oncology · 368
PDF
Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors
2016 · Ann-Gerd Thorsell, Torun Ekblad, et al. · Journal of Medicinal Chemistry · 358
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
2023 · Kim N. Chi, Dana Rathkopf, et al. · Journal of Clinical Oncology · 355
PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline
2020 · William P. Tew, Christina Lacchetti, et al. · Journal of Clinical Oncology · 315
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer
2020 · Anniina Färkkilä, Doga C. Gulhan, et al. · Nature Communications · 300
PDF
Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors
2015 · Todd A. Hopkins, Yan Shi, et al. · Molecular Cancer Research · 270
Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models
2019 · Zebin Wang, Kaiming Sun, et al. · Scientific Reports · 252
PDF
Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial
2019 · Mansoor Raza Mirza, Elisabeth Åvall Lundqvist, et al. · The Lancet Oncology · 242
Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors
2018 · Isabella Faraoni, Grazia Graziani · Cancers · 232
PDF
Trapping Poly(ADP-Ribose) Polymerase
2015 · Yuqiao Shen, Mika Aoyagi-Scharber, et al. · Journal of Pharmacology and Experimental Therapeutics · 227
Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial
2023 · K.N. Chi, S. Sandhu, et al. · Annals of Oncology · 219
PDF
PARP inhibitors in ovarian cancer
2018 · Elisena Franzese, Sara Centonze, et al. · Cancer Treatment Reviews · 212
PDF
Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial☆
2021 · X.H. Wu, J.Q. Zhu, et al. · Annals of Oncology · 201
PARP Inhibitors in Ovarian Cancer: A Review
2023 · David M. O’Malley, Thomas C. Krivak, et al. · Targeted Oncology · 192
PDF
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial
2022 · Matthew R Smith, Matthew R Smith, et al. · The Lancet Oncology · 190
PDF
Works count: 2,534
Citation count: 33,870
Year
Topic
Type